TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01254123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide infusion
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion.
Description: On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours.
Study: NCT02151266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive retraining
Description: Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Only

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stretching and Flexibility
Study: NCT03343197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881
Description: Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
Study: NCT01349920

Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
Study: NCT01811212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00812279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distillation based smoking article (SMAR cigarette)
Description: Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional cigarette
Description: Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
Study: NCT01458470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: oral tablet, 1 BID, 24 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, 1 BID, 24 weeks
Study: NCT04167605

Intervention type: OTHER
Intervention: Bone metastasis
Description: Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.

Intervention type: OTHER
Intervention: Breast cancer metastatic to bone
Description: Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
Study: NCT01185067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Description: Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
Description: Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
Study: NCT01942681

Intervention type: DRUG
Group type: OTHER
Intervention: Propiverine Hydrochloride
Description: Administrate Propiverine Hydrochloride for 12 weeks
Study: NCT04272502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Description: Each arm has a different order for taking IP
Study: NCT01780038

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No results given
Description: Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
Study: NCT04272502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Description: Each arm has a different order for taking IP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-348 F1, CKD-348 F2, CKD-828, D326, D337
Description: Each arm has a different order for taking IP
Study: NCT03735264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT02244255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOMAX® capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascending doses of HYTRIN® capsules
Study: NCT02635802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil+Lidocaine
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
Study: NCT02741401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual post-operative care
Description: Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual post-operative care
Description: Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot massage
Description: Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
Study: NCT01995487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioNIR
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute
Description: drug-eluting stent
Study: NCT04523155

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically tailored meals
Description: 10 meals per week for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medically tailored meals
Description: 10 meals per week for 3 months
Study: NCT04602884

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath biopsy sampling using the ReCIVA Breath Sampler
Description: Breath biopsy sampling using the ReCIVA Breath Sampler

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath biopsy sampling using the ReCIVA Breath Sampler
Description: Breath biopsy sampling using the ReCIVA Breath Sampler
Study: NCT02707692

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .
Study: NCT00843609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigator continuous glucose monitor (Freestyle Navigator®)
Description: Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
Study: NCT02707692

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluarix
Description: Intramuscular injection with Fluarix® .

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax
Description: Intramuscular injection with Pneumovax.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).
Study: NCT00513461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study: NCT03909061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair Maintenance Training
Description: Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair Maintenance Training
Description: Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wheelchair Maintenance Training
Description: Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
Study: NCT02707692

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Intramuscular injection with sterile saline (placebo).
Study: NCT01323530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous (IV) bolus or infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Intravenous (IV) bolus or infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral film-coated tablets.
Study: NCT00742079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
Study: NCT01635608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administration of 500 mg paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administration of 500 mg paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talinolol
Description: administration of 50 mg talinolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talinolol
Description: administration of 50 mg talinolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: administration of 500 mg amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: administration of 500 mg amoxicillin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-caloric water
Description: administration of 240 ml water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: caloric water
Description: administration of 240 ml caloric water (containing 25.5 g sucrose)
Study: NCT04536246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Quadriceps Tendon (BQT) arthroscopic-assisted ACL reconstruction
Description: New intervention method deployed in Indonesia to gain better clinical outcome for ACL--deficient patients requiring surgical treatment
Study: NCT03867136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZA sensitivity guided ultra-short all Oral Regimen
Description: Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, \>50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, \>50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Shorter Regimen
Description: Pyrazinamide 1500 mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, \>50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, \>50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. All treatment is taken daily.
Study: NCT02694783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PyVST
Description: ex vivo generated polyomavirus-specific T cells from HLA-matched donor
Study: NCT03524235

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Pre-Transplantation Total Body Irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Stem Cell Transplantation
Description: Haploidentical Stem Cell Transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD56-Enriched Donor Lymphocyte Infusion
Description: CD56-Enriched Donor Lymphocyte Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Pre-Transplantation Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Pre-Transplantation Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
Study: NCT04300309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether:lumefantrine (2.5 mg:30 mg)
Description: Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.
Study: NCT03991962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
Study: NCT02346968

Intervention type: OTHER
Intervention: Blood and urine sampling
Description: Blood and urine sampling (in the context of routine sampling)
Study: NCT00513461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies
Study: NCT02314377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
Study: NCT02015793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection.
Study: NCT05338502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study: NCT00513461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies
Study: NCT03570996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal
Study: NCT05338502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally.